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Abstract
Background: Mutations in SLC26A4 cause Pendred syndrome (hearing loss with goiter) or DFNB4 (non-syndromic
hearing loss with inner ear malformation, such as enlarged vestibular aqueduct or Mondini deformity). The
relationship between mutations in SLC26A4 and Mondini deformity without enlarged vestibular aqueduct has not
been studied in any Chinese deaf population. The purpose of this study was to assess whether mutations in the
SLC26A4 gene cause Mondini deformity without an enlarged vestibular aqueduct (isolated Mondini deformity) in a
Chinese population.
Methods: In total, 144 patients with sensorineural hearing loss were included and subjected to high-resolution
temporal bone CT. Among them, 28 patients with isolated Mondini dysplasia (MD group), 50 patients with
enlarged vestibular aqueduct with Mondini dysplasia (EVA with MD group), 50 patients with enlarged vestibular
aqueduct without Mondini dysplasia (EVA group), and 16 patients with other types of inner ear malformations (IEM
group) were identified. The coding exons of SLC26A4 were analyzed in all subjects.
Results: DNA sequence analysis of SLC26A4 was performed in all 144 patients. In the different groups, the detection
rate of the SLC26A4 mutation differed. In the isolated MD group, only one single allelic mutation in SLC26A4 was
found in one patient (1/28, 3.6%). In the EVA with MD group, biallelic and monoallelic SLC26A4 mutations were
identified in 46 patients (46/50, 92.0%) and three patients (3/50, 6.0%), respectively. Also, in the EVA group, biallelic
and monoallelic SLC26A4 mutations were identified in 46 patients (46/50, 92.0%) and three patients (3/50, 6.0%),
respectively. These percentages were identical to those in the EVA plus MD group. Only two patients carried
monoallelic mutations of the SLC26A4 gene in the IEM group (2/16, 12.5%). There were significant differences in the
frequency of SLC26A4 mutation among the groups (P < 0.001). The detection rate of SLC26A4 mutation in the
isolated MD group was significantly lower than in the EVA group (with or without MD; P < 0.001), and there was no
significant difference in the detection rate of SLC26A4 between the MD group and IEM group (P > 0.5).
Conclusion: Although mutations in the SLC26A4 gene were frequently found in Chinese EVA patients with and
without MD, there was no evidence to show a relationship between isolated MD and the SLC26A4 gene in the
Chinese population examined. Hearing impairment in patients with isolated MD may be caused by factors other
than mutations in the SLC26A4 gene.
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Hearing impairment is the most common neurosensory
disorder in humans with congenital or prelingual deaf-
ness, affecting about 1 in 300 to 1 in 1000 children
[1-3]. Approximately half of cases have a genetic etiol-
ogy, including syndromic and non-syndromic forms,
with extraordinary genetic heterogeneity. Non-syndro-
mic deafness accounts for 60-70% of inherited hearing
impairment. It involves more than 100 different genes
with autosomal dominant (DFNA), autosomal recessive
( D F N B ) ,X - l i n k e d( D F N ) ,a n dmaternal inheritance [4];
autosomal recessive is the most common. Mutations in
the SLC26A4 gene are probably the second most com-
mon cause of inherited hearing loss, after GJB2 muta-
tions, and are responsible for Pendred syndrome as well
as DFNB4 (non-syndromic hearing loss with inner ear
abnormalities, such as enlarged vestibular aqueduct
(EVA) with or without Mondini dysplasia (MD)) [5,6].
Enlarged vestibular aqueduct syndrome (EVAS) and
MD are the most frequently encountered radiographic
anomalies of the inner ear. The most accepted criterion
for definition of a large vestibular aqueduct is that sug-
gested by Valvassori [7]: a vestibular aqueduct is consid-
ered to be enlarged if its diameter is > 1.5 mm at the
midpoint between the common crus and the external
aperture of the vestibular aqueduct on CT images. The
imaging diagnostic criterion is differet about Mondini
malformarion. Mondini first described by Carlo Mondini
in 1791[8]detailed a small cochlea completing only one
and a half turns and lacking a complete interscalar sep-
tum, addtionally, he described a bulbous endolymphatic
sac and a dilated vestibular aqueduct. Since then, the
term “Mondini” h a sb e e nu s e da sa nu m b r e l l at e r mi n
clinical practice to describe almost any type of congeni-
tal cochlear deformity, included temporal bones with a
common cavity and an incomplete interscalar septum of
the cochlea. And a Mondini cochlea (isolated Mondini)
occurs only when the two and a half turns of the
cochlea are replaced by a single cavity in the apical
region because of the absence of the interscalar septum
[9-11]. It is usually bilateral and frequently associated
with other inner ear malformations (IEMs) such as cys-
tic expansion of the vestibules and semicircular canal
dysplasia. Temporal bone abnormalities, ranging from
isolated EVA to MD, have been causally linked to muta-
t i o n si nt h ea n i o nt r a n s p o r t e rg e n eSLC26A4,w h i c h
encodes the protein pendrin [5]. Pourova [12] found
that 40.9% of Czech EVA/MD patients carried SLC26A4
mutations (27.3% had biallelic mutations and 13.6% had
monoallelic mutations), and the detection rate of
SLC26A4 mutations in Italian patients was 30% in
Bogazzi’s research [13]. These observations suggest that
SLC26A4 mutations are frequently present in patients
with EVA or MD. In the Chinese deaf population,
SLC26A4 was also found to have a close relationship
with the pathogenesis of DFNB4 [14,15], but no sys-
tematic study was appliedt oe x a m i n et h er o l eo f
SLC26A4 in the pathogenesis of isolated Mondini.
To understand the molecular etiology of isolated MD
(MD without EVA) and provide possible genetic testing
and counseling for hearing loss patients with isolated
MD in China, we performed SLC26A4 sequence analysis
in 28 patients with isolated MD, 50 patients with EVA
and MD, 50 patients with isolated EVA, and 16 patients
with other forms of IEM. In this study, the imaging
diagnostic criterion of isolated Mondini is a cochlea of
one and a half turns instead of the normal two and a
half turns, comprising a normal basal turn and a cystic
apex.
Materials and methods
Patients
In total, 144 patients with sensorineural hearing loss
(from unrelated families) were reached through the Oto-
laryngology Department of Chinese PLA General Hospi-
tal and included in this study. High-resolution temporal
bone CT was available for all 144 recruited patients. Iso-
lated MD was defined as a complex malformation in
which the normal cochlear two and a half turn spirals
w e r er e p l a c e db yah y p o p l a s t i cc o i lo fo n ea n dah a l f
turns because of an absence of the interscalar septum.
EVA was considered to be enlarged if its diameter was >
1.5 mm at the midpoint between the common crus and
the external aperture of the vestibular aqueduct. Based
on the image information in these 144 patients, isolated
MD was identified in 28 patients (19.4%), EVA with MD
was identified in 50 patients (34.7%), EVA without MD
was identified in 50 patients (34.7%), and other types of
IEM were identified in 16 patients (11.1%). The other
types of IEM included six cases of cystic cochlea, dilated
vestibule, and enlarged internal auditory canal, two
cases of common cavity (a cystic cavity representing the
cochlea and vestibule without showing any differentia-
tion into cochlea and vestibule), semicircular canal apla-
sia, and narrow internal auditory canal, one case of
semicircular canal hypoplasia, one case of inner ear ossi-
fication, one case of vestibule and semicircular ossifica-
tion, three cases of common cavity and enlarged
internal auditory canal, one case of common cavity, and
one case of common cavity with narrow internal audi-
tory canal (Figure 1). Of the 144 patients, 82 were males
and 62 were females. Ages ranged from 10 months to
25 years. In isolated MD group, ages ranged from 14
months to 26 years and the average age was 8 years. In
EVA with MD group, ages ranged from 8 months to 29
years and the average age was 11 years. In EVA group,
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age was 10 years, and in IEM group, ages ranged from
15 months to 27 years and the average age was 10 years.
Clinical evaluation
A complete history, physical and otoscopic examina-
tions, and audiological testing, including pure tone
audiometry, tympanometry, or auditory brainstem
response, were carried out in all patients. No patient
was found to have any goiter symptom or sign or syn-
dromic symptoms in other systems. Pure-tone average
(PTA) was calculated as the average of the threshold
measured at 0.5, 1.0, 2.0, and 4.0 kHz and was used to
compare subgroups of patients. The level of hearing
loss, in terms of PTA, was described as follows: normal
hearing, < 20 dB; mild hearing impairment, 21-40 dB;
moderate hearing impairment, 41-70 dB; severe hearing
impairment, 71-90 dB; and profound hearing impair-
ment, > 91 dB.
Mutational analysis
Informed consent was obtained from all participants or
the parents of minors prior to blood sampling. This
study was performed according to the protocol approved
by the Ethics Committee of the Chinese PLA General
Hospital.
DNA was extracted from peripheral blood leukocytes
using a commercially available DNA extraction kit
(Watson Biotechnology, Inc., Shanghai, China). DNA
sequence analysis of the SLC26A4 gene was performed
by polymerase chain reaction amplification of the 21
coding exons plus approximately 50-100 bp of the flank-
ing intron regions with previously published primers
[16]. The reaction mixture contained 100 ng DNA, 1.5
units of DNA Taq polymerase(TaKaRa, Dalian, China),
200 uM dNTPs, 3 pmol of each forward and reverse pri-
m e r ,2 . 5u lo f1 0×b u f f e r ( w i t h2 . 5m MM g C l 2) and the
final reaction volume was filled to 25ul with ddH2O.
The exons in the gene were amplified according to the
PCR conditions described previously [17,18]. The PCR
amplified products were sequenced and analyzed using
an ABI 3130 DNA sequencing machine (ABI, Foster
City, CA, USA) and the ABI 3130 Analysis Software
(v.3.7 NT) according to the manufacturer’s instructions.
Statistical testing
The distribution of SLC26A4 in the different groups
belongs to nonparametric randomized block design
information. The Friedman rank sum test (M-test) was
used to determine whether there was a significance dif-
ference in the observed number of mutant SLC26A4
g e n e si nt h ei s o l a t e dM D ,E V Aw i t hM D ,E V A ,a n d
IEM groups [19]. The chi-squared test(R × C table) was
used to compare the hearing level among the four
groups[20]. All statistical methods were analyzed on
SPSS (statistical package for the Social Sciences)15.0
software. A P-value of 0.05 or less was accepted as sta-
tistically significant.
Results
The hearing loss phenotype ranged from moderate to
profound. Table 1 shows the distribution of hearing
Figure 1 Typical CT scan images of MD, EVA with MD, EVA, and other inner ear malformations.a .M D ;b .E V Aw i t hM D ;c .E V A ;d .
common cavity (a cystic cavity representing the cochlea and vestibule without showing any differentiation into cochlea and vestibule); e.
narrow internal auditory canal; f. internal auditory canal enlarged; g. inner ear ossification; h. cochlear, vestibular, and semicircular canal
hypoplasia.
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and IEM groups. Most patients in the four groups had
severe to profound hearing loss, but there was no differ-
ence in the distribution of hearing level among the four
groups.
DNA sequence analysis of SLC26A4 was performed in
all 144 patients. Biallelic, monoallelic, and no SLC26A4
mutations were detected in 92 patients (63.9%), nine
patients (6.3%), and 43 patients (29.9%), respectively. In
the different groups, the detection rate of the SLC26A4
mutation was discrepant (Table 2).
In the isolated MD group, only one monoallelic muta-
tion in SLC26A4 (c.919-2A>G, aberrant splicing) was
found in one patient (1/28, 3.6%), and no mutation was
found in the other 27 patients (27/28, 96.4%). In the
EVA with MD group, biallelic, monoallelic, and no
SLC26A4 mutations were identified in 46 patients (46/
50, 92.0%), three patients (3/50, 6.0%), and one patient
(1/50, 2.0%), respectively. In the EVA groups, biallelic,
monoallelic, and no SLC26A4 mutations were identified
in 46 patients (46/50, 92.0%), three patients (3/50, 6.0%),
and one patient (1/50, 2.0%), respectively. Similar to the
isolated MD group, only two patients were identified to
carry monoallelic mutations of the SLC26A4 gene in the
IEM group (2/16, 12.5%). Among them, one patient car-
ried the c.919-2A>G mutation, and the other carried the
c.1286C>A(p.A429E) mutation. All variants of SLC26A4
found in the EVA plus MD group and EVA group are
listed in Table 3.
In this study, in total, 39 SLC26A4 mutations were
found among the 144 patients. Most SLC26A4 muta-
tions (97%, 38/39) were found in the EVA group and
the EVA with MD group, with the exception of one sin-
gle allelic mutation (c.919-2A>G) in the isolated MD
group and two single allelic mutations (c.919-2A>G and
c.1286C>A) in the group with other IEM. Some muta-
tions observed in present work, as indicated in Table 3
were previously reported to be pathogenic. Among these
previously reported mutations, c.919-2A>G (51%, 102/
200) was the most prevalent in the EVA with MD and
EVA groups. The mutations p.H723R, p.T410M, p.
V659L, and p.N392Y were also more common than the
others in both groups (Table 3). Thirteen variants had
not been previously reported (Table 3), consisting of
seven missense variants (c.1286C>A(p.A429E),
c.1594AG>T(SF532,545*), c.563T>C (p.I188T),
c.1225C>T(p.R409C), c.1173C>A(p.S391R), c.2086C>T
(p.Q696*), and c.1991C>T (p.A664V)), five deletions
(c.1520delT, c.496delA, c.414delT, c.1339-1340delA, and
c.218delA), and one splice site variant (c.ivs9+1G>A).
Among the novel variants, c.1594AG>T(SF532,545*),
c.2086C>T(p.Q696*), c.1520delT(SF507,507*), c.496delA
(SF166, 171*), c.414delT(SF138, 144*), c. 1340delA
(SF447, 454*), and c.218delA(SF73, 96*) encode either
frameshift or nonsense mutations, resulting in early
translational termination, severe truncation of the pen-
drin polypeptide, and, very likely, non-functional and/or
unstable polypeptide products. The novel splice site (c.
ivs9+1G>A) and five missense mutations (p.A429E, p.
I188T, p.R409C, p.S391R, p.A664V) affect residues that
are conserved among SLC26A4 orthologs [Mus (mouse),
Macaca, Rattus, Bos, Danio; Figure 2]. These mutations
were not present in a screen of 50 patients without IEM
and 200 normal Chinese controls in Yuan’s research [6],
suggesting that these five mutations are also likely to be
pathogenic.
The statistical analysis showed that there were signifi-
cant differences in the frequency of SLC26A4 mutation
among the groups (P < 0.001). In the isolated MD
group, only one single allelic mutation in SLC26A4 was
found in one patient (1/28, 3.6%). In the EVA with MD
group, 46 patients (46/50, 92.0%) carried biallelic muta-
tions, and three patients carried single allelic mutations
(3/50, 6.0%). In the EVA group, 46 patients (46/50,
92.0%) had biallelic mutations and three patients with
one mutation (3/50, 6.0%). Only two patients carried
single allelic mutations of the SLC26A4 gene in the IEM
group (2/16, 12.5%). The distribution of SLC26A4 muta-
tion in the isolated MD group was significantly lower
Table 1 Hearing levels in the different groups
Hearing level MD EVA with MD EVA IEM
Moderate 2 5 4 1
Severe 6 17 14 5
Profound 20 28 32 10
MD: Isolated Mondini dysplasia, EVA with MD: enlarged vestibular aqueduct
with Mondini dysplasia, EVA: enlarged vestibular aqueduct without Mondini
dysplasia, IEM: other types of inner ear malformations
Table 2 Distribution of SLC26A4 mutations in the different groups
Inner ear image No mutation Monoallelic mutation Biallelic mutation Total
MD 27 (96.4%) 1 (3.6%) 0 28 (100%)
EVA with MD 1 (2.0%) 3 (6.0%) 46 (92.0%) 50 (100%)
EVA 1 (2.0%) 3 (6.0%) 46 (92.0%) 50 (100%)
IEM 14 (87.5%) 2 (12.5%) 0 16 (100%)
Total 43 9 92 144
MD: Isolated Mondini dysplasia, EVA with MD: Enlarged vestibular aqueduct with Mondini dysplasia, EVA: enlarged vestibular aqueduct without Mondini
dysplasia, IEM: Other types of inner ear malformations
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CT phenotype Patient number Genotype of SLC26A4
allele 1 allele 2
nucleotide change amino acid change nucleotide change amino acid change
Isolated MD 1 c.919-2 A>G[21] aberrant splicing - -
(1-28) 2-28 - - - -
IEM 29 c.919-2 A>G aberrant splicing - -
(29-44) 30 1286C>A (this study) A429E - -
31-44 - - - -
EVA 45 c.917insG(6) Frameshift - -
(45-94) 46-57 c.919-2 A>G aberrant splicing c.919-2 A>G aberrant splicing
58 c.1226G>A[22] R409H c.1226G>A R409H
59 c.919-2 A>G aberrant splicing c.1520delT(this study) Frameshift
60 c.919-2 A>G aberrant splicing c.1343C>A[23] S448*
61 c.1174A>T[24] N392Y c.1975G>C[25] V659L
62-65 c.919-2 A>G aberrant splicing c.2168A>G[21] H723R
66 c.1229C>T[26] T410M c.1079C>T[27] A360V
67 c.2027T>A[23] L676Q c.ivs15+5G>A[26] aberrant splicing
68,69 c.919-2 A>G aberrant splicing c.1229C>T T410M
70 c.919-2 A>G aberrant splicing c.1829C>A[21] S610*
71,72 c.919-2 A>G aberrant splicing c.1343C>T[23] S448L
73 c.1229C>T T410M c.1594AG>T (this study) SF532, 545*
74,75 c.919-2 A>G aberrant splicing c.1975G>C V659L
76,77 c.919-2 A>G aberrant splicing c.946G>T(6) G316X
78 c.919-2 A>G aberrant splicing c.ivs9+1G>A (this study) aberrant splicing
79,80 c.919-2 A>G aberrant splicing c.1586T>G[23] I529S
81 c.2168A>G H723R - -
82 c.2168A>G H723R c.2168A>G H723R
83 - - - -
84 c.919-2 A>G aberrant splicing c.281C>T[23] T94I
85 c.919-2 A>G aberrant splicing - -
86 c.919-2 A>G aberrant splicing c.1318A>T[23] K440*
87 c.919-2 A>G aberrant splicing c.563T>C(this study) I188T
88 c.919-2 A>G aberrant splicing c.496delA (this study) Frameshift
89 c.919-2 A>G aberrant splicing c.1318A>T K440*
90 c.812A>G[23] D271G c.1225C>T (this study) R409C
91 c.919-2 A>G aberrant splicing c.1548insC[26] Frameshift
92 c.919-2 A>G aberrant splicing c.1173C>A (this study) S391R
93 c.919-2 A>G aberrant splicing c.1174A>T N392Y
94 c.2168A>G H723R c.2T>C[16] M1T
EVA with MD 95 - - - -
(95-140) 96-99 c.919-2 A>G aberrant splicing c.2168A>G H723R
100-102 c.919-2 A>G aberrant splicing c.589G>A[23] G197R
103 c.2168A>G H723R c.1594AG>T SF532, 545*
104-115 c.919-2 A>G aberrant splicing c.919-2 A>G aberrant splicing
116 c.919-2 A>G aberrant splicing c.1238A>G[28] Q413R
117 c.919-2 A>G aberrant splicing c.414delT (this study) Frameshift
118 c.1229C>T T410M c.1343C>A S448*
119 c.2168A>G H723R c.754T>C[26] S252P
120,121 c.919-2 A>G aberrant splicing c.ivs13+9C>T[29] aberrant splicing
122,123 c.919-2 A>G aberrant splicing c.1229C>T T410M
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0.001), suggesting that mutations in the SLC26A4 gene
are more frequently associated with the EVA phenotype.
There was no significant difference between the isolated
MD and IEM groups (P > 0.5) and no difference in
mutation distribution between the EVA with MD group
and EVA group (P > 0.5). Yuan’s research [6] identified
four carriers of heterozygous c.919-2A>G among 200
Chinese individuals with normal hearing. There was no
significant difference in mutation distribution between
isolated MD patients and Yuan’s research (P > 0.5).
Discussion
DNA sequence analysis for SLC26A4 mutations was per-
formed in 144 patients with sensorineural hearing loss
in this study. Inner ear malformation was present
Figure 2 Sequence alignment of partial amino acid sequence of human SLC26A4 and its homologs. Positions of mutations are indicated
in blue.
Table 3 Distribution of SLC26A4 genotypes in patients with different CT scan phenotype (Continued)
124 c.1174A>T N392Y c.2027T>A L676Q
125-127 c.919-2 A>G aberrant splicing c.1975G>C V659L
128 c.2168A>G H723R c.1079C>T A360V
129,130 c.919-2 A>G aberrant splicing c.2027T>A L676Q
131 c.919-2 A>G aberrant splicing c.1340delA(this study) Frameshift
132 c.1174A>T N392Y - -
133 c.919-2 A>G aberrant splicing c.218delA(this study) Frameshift
134 c.2168A>G H723R c.2086C>T(this study) Q696*
135 c.ivs15+5G>A aberrant splicing c.1520delT Frameshift
136,137 c.919-2 A>G aberrant splicing c.1226G>A R409H
138,139 c.919-2 A>G aberrant splicing - -
140 c.919-2 A>G aberrant splicing c.1991C>T(this study) A664V
140 c.2168A>G H723R c.439A>G[21] M147V
140 c.919-2 A>G aberrant splicing c.1594A>C[23] S532R
140 c.919-2 A>G aberrant splicing c.ivs15+5G>A aberrant splicing
140 c.1174A>T N392Y c.1174A>T N392Y
Isolated MD group: Patient 1 had only one mutation and patient 2-28 had no mutation in SLC26A4. IEM group: Patient 29, 30 had one mutation and patient 31-
44 had no mutation in SLC26A4. EVA group: Most patients had bi-allelic mutations except Patient 45, 81, 85 had one mutation and patient 83 had no mutation in
SLC26A4. EVA with MD group: Most patients had bi-allelic mutations except Patient 132, 138, 139 had one mutation and patient 95 had no mutation.
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with MD, isolated EVA (without MD), and other IEM
identified on temporal bone CT scan images. The muta-
tion detection rates of SLC26A4 were 3.6%, 98%, 98%,
and 12.5% in the isolated MD group, EVA with MD
group, EVA group, and IEM group, respectively. The
prevalences of biallelic mutations in SLC26A4 were 0%,
92%, 92%, and 0%, and prevalences of monoallelic muta-
tions were 3.6%, 6.0%, 6.0%, and 12.5% in the four
respective aforementioned groups. The detection rate of
SLC26A4 mutations in patients with EVA with or with-
out MD in this study were consistent with the frequen-
cies in other Asian studies, which are 87%, 97.9%, 92%,
and 78% in Taiwanese, Chinese, Japanese, and Korean
EVA patients, respectively [6,21,26,30]. Meanwhile, the
mutation detection rate of this gene in Caucasian EVA
patients is much lower, at 53% and 40%, respectively, in
the UK and Europe [31,32]. In the US population, muta-
tions in SLC26A4 account for about one-third of EVA
patients [33]. In these studies, however, the researchers
did not clearly define the specific concept of Mondini.
Azaiez [34] presented a comprehensive analysis of 474
patients from the Molecular Otolaryngology Research
Laboratories of the University of Iowa Hospital and Clinics
(most patients were Caucasians) with temporal bone
anomalies to determine the correlation between SLC26A4
genotypic and phenotypic data. In Azaiez’ss t u d y ,M o n d i n i
was diagnosed a complex malformation that includes a
cochlear dysplasia and EVA (EVA with MD). This study
showed that 24.1% (28/116) of patients diagnosed EVA
with MD had biallelic mutations in SLC26A4,b u to n l y
11.1% (38/341) of patients with isolated EVA had biallelic
mutations in SLC26A4. There was a statistically significant
difference in mutation distribution between isolated EVA
patients and EVA with MD patients, with the presence of
mutations in SLC26A4 more frequently associated with
the EVA with MD phenotype. Azaiez suggested that muta-
tions in SLC26A4 were more likely to be of a genetic etiol-
ogy in EVA with MD than in EVA, in the other side of the
spectrum, the environment is believed to play a bigger role
in isolated EVA patients. In Campbell’s research [35], 57%
of patients from the US with Mondini (EVA with MD)
from simplex families carried SLC26A4 mutations, and he
considered that SLC26A4 mutations were present mostly
in patients with EVA plus MD. The observations in the
present study were not consistent with either Azaiez or
Campbell’s findings. There was no difference in the distri-
bution or mutation frequency between the EVA group
and EVA with MD group in our study. The mutation
detection rate in SLC26A4 was 98% in both the EVA with
MD group and the EVA group, and the percentage of
patients with biallelic mutations was 92% and in both
groups.
SLC26A4 encodes pendrin, an anion transporter pro-
tein [10]. In the inner ear, pendrin is expressed in cells
of the external sulcus, epithelial cells of the endolym-
phatic duct and sac, and nonsensory cells at the margin
of the maculae of the utricle and saccule. In all of these
cell types, the apical surface is exposed to endolymph,
consistent with pendrin’s role as an anion transporter.
The variant of pendrin was able to exchange anions
between the cytosol and extracellular fluid [36]. Table 3
shows that the SLC26A4 mutations c.919-2A>G and p.
H723R were highly prevalent in both in the EVA with
MD and EVA groups, and the mutation spectrums were
also very similar between the two groups. Our data pro-
vides strong evidence that the molecular pathogenesis of
EVA with or without MD were identical solely because
of the similar ORF mutation spectrum in SLC26A4 in
the Chinese population and that the ORF mutations in
SLC26A4 were not likely to be the reason for the patho-
genesis of isolated MD in this Chinese population. So it
is reasonable that there were the same mutation detec-
tion rates of SLC26A4 in both the EVA with MD group
and the EVA group in this study.
The most significant mechanistic insights into the
pathogenesis of hearing loss associated with EVA are
based upon the SLC26A4 knockout (SLC26A4-/-) mouse
that segregates a targeted deletion of exon 8 of
SLC26A4 [37] and the loop mouse line segregating a
chemically induced mutation of SLC26A4 [38]. In the
mouse inner ear, pendrin is expressed in the cochlea,
the vestibular labyrinth and the endolymphatic sac and
pendrin functions as a Cl
-/HCO3
- exchanger. The initial
pathologic alterarion in SLC26A4-/- mice includes an
enlargement of the endolymphatic sac and cochlea that
develops at E14.5 [39]. Studies of an SLC26A4 knockout
mouse demonstrate that acidification and enlargement
of the scala media are early events in the pathogenesis
of deafness. The enlargement is driven by fluid secretion
in the vestibular labyrinth and a failure of fluid absorp-
tion in the embryonic endolymphatic sac.
Our data showed that the distribution of SLC26A4
mutation in the isolated MD group was significantly
lower than that in the EVA with or without MD
patients; the one patient from the MD group who car-
ried a monoallelic mutation of SLC26A4 (c.919-2A>G)
might have been a coincident carrier of this mutation.
There was no significant difference among the MD
group, IEM group (P > 0.5), and normal controls (pre-
vious data published by Yuan [6]). Our results did not
show a relationship between isolated MD and the
SLC26A4 gene in this Chinese population. The hearing
impairment in our MD group might have been caused
by factors other than the SLC26A4 gene in our Chinese
population.
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fourth week of embryonic life. The inner ear consists of
two components: a membranous and a bony labyrinth.
The membranous labyrinth is derived from the ecto-
derm, whereas the bony labyrinth/otic capsule is derived
from the mesoderm and neural crest surrounding the
primordial membranous labyrinth. The primordium of
the cochlear duct evaginates from the ventral portion of
the otocyst starting at the fifth week. This evagination
extends anteromedially and gradually begins to coil. By
the eighth week, the cochlea has formed 1.5 turns, and
at the tenth week, 2 turns; at the 25
th week, the cochlear
duct has acquired the mature 2.5 turns. Ossification of
the cartilaginous capsule to form the bony labyrinth
does not occur until the membranous labyrinth has
acquired its adult size. Bone formation starts at the 15
th
week and ends by the 21
st week, with a total of 14 ossi-
fication centers [40]. In cochlear Mondini, it is thought
that the arrest of development is at the seventh week of
gestation. During inner ear development, many genes
causing IEM and deafness have been identified, includ-
ing SLC26A4, EYA1 [41], FGFR3 [42,43], and TCOF1
[44,45]. Pathological analysis performed on hearing
impaired patients revealed the presence of Mondini dys-
plasia, characerized by a reduced number of cochlear
turns and a incomplete interscalar sptum [46,47].
Mouse models have made it possible to study the mole-
cular origins of the ear pathology found in both VCFS/
DGS and DFN3. Mice homozygous null for Tbx1 die at
birth and exhibit severe ear defects due to early arrest of
inner ear development [48]. Additionally, some Brn4
null mice display a reduction in cochlear coiling. The
normal mouse cochlea consist of 1.75 turns; however,
approximately 25% of Brn4 null mice have less than 1.5
turns, indicating a role for Brn4 in epithelial-mesenchy-
mal interactions during ear development[49]. With the
exception of the aforementioned genes, it was evident to
clinicians that retinoids (vitamin A) or other factors had
potent teratogenic effects in isolated MD patients when
administered early in pregnancy [50]. These factors
increase the complexity of determining the real etiology
of isolated MD, and our observations hint that ethnic
background is apparently important and may affect the
etiologic explanation of isolated MD. We suggest that
EVA with or without MD and isolated MD in this Chi-
nese population have totally different pathogenic
mechanisms.
Conclusion
We did not review the relationship between SLC26A4
and isolated MD in a Chinese deaf population, but we
provided evidence to support the idea that mutations in
SLC26A4 were the most important factor in the patho-
genesis of EVA with and without MD. This will facilitate
genetic testing and counseling in patients with different
types of inner ear malformation, and may provide moti-
vation to explore the real etiology of isolated MD by
new genomic strategies and platforms, such as capturing
and sequencing all possible genes related to the develop-
ment of the inner ear using next-generation sequencing
technology.
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